1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Peak Bio, Inc.

Peak Bio, Inc.

PKBOW
Peak Bio, Inc.US flagNASDAQ Global Market
0.01
USD
+0.01
- -
531,873.00Market Cap
Peak Bio, Inc.
PKBOW
(NASDAQ Global Market)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
TTM
FRC
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
Operating Margin (%)
- -
1
- -
- -
Depreciation Expense
-8
-13
-13
-3
Net Income, GAAP
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
-2
-8
-18
-21
Working Capital
- -
4
- -
- -
LT Debt
-2
-8
-18
-21
Total Equity
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
-3.81
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
12
12
10
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
2
1
2
Cash, Cash Equivalents & STI
- -
- -
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
22
24
22
Payables & Accruals
6
6
7
ST Debt
12
12
10
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
124.31%
Free Cash Flow
- -
- -
-37.62%
Net Income, GAAP
- -
- -
-2.01%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Xiamen Amoytop Biotech Co., Ltd. (688278.SS)
Atai Beckley Inc. (ATAI)
POINT Biopharma Global Inc. (PNT)
EyePoint Pharmaceuticals, Inc. (EYPT)
Novavax, Inc. (NVAX)
RAPT Therapeutics, Inc. (RAPT)
Business
Peak Bio, Inc. (OTC: PKBOW) is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing significant unmet medical needs in oncology, inflammation, rare and specialty diseases. The company offers a pipeline featuring PHP-303, a Phase 2-ready small molecule neutrophil elastase inhibitor for alpha-1 antitrypsin deficiency disorder (AATD); an antibody-drug-conjugate (ADC) platform incorporating novel toxins such as PH-1 (Thailanstatin), a spliceosome modulator, linkers and cancer-targeting antibodies; and additional programs targeting solid tumors through immune-engaging payloads. Peak Bio, founded in 2015, maintains headquarters in Palo Alto, California, with research operations in the United States and Korea, serving patient populations in autoimmune, inflammatory and oncologic indications. In November 2024, Peak Bio completed a merger with Akari Therapeutics, Plc (Nasdaq: AKTX) in an all-stock transaction as equals, forming a combined entity that continues as Akari Therapeutics with expanded focus on ADCs, geographic atrophy therapies and complementary assets, supported by PIPE financing and an equity line of credit; the merger followed shareholder approval and aims to advance milestones in oncology and inflammatory diseases while addressing Nasdaq compliance.